Shasha Zhang, Leiyan Su, Zefeng Kang, Shoukang Zhang, Jing Wang
Department of Ophthalmology, Eye Hospital, China Academy of Chinese Medical Sciences, Beijing 100040, China;For correspondence:- Leiyan Su Email:
Accepted: 22 June 2023 Published: 31 July 2023
Citation: Zhang S, Su L, Kang Z, Zhang S, Wang J. Effect of co-administration of pranoprofen/emedastine difumarate eye drops on efficacy, inflammatory factors, tear film stability and immune function in children with allergic conjunctivitis. Trop J Pharm Res 2023; 22(7):1495-1502 doi: 10.4314/tjpr.v22i7.20
© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To investigate the clinical efficacy of pranoprofen eye drops when combined with emedastine difumarate eye drops for the treatment of children with allergic conjunctivitis.
Methods: A total of 96 children with allergic conjunctivitis admitted to Eye Hospital, China Academy of Chinese Medical Sciences from January 2020 to 2022 were enrolled in this study. They were divided into study group (treated with both pranoprofen eye drops and emedastine difumarate eye drops), and control group (treated with emedastine difumarate eye drops alone), with 48 children in each group. The control group was given emedastine fumarate eye drops 1 drop twice a day. The study group was given pranoprofen eye drops 2 drops 4 times a day in addition to the treatment administered to control group. Patients in both groups were observed and compared after one week of treatment. Efficacy, incidence of adverse reactions, symptom scores, inflammatory factors, tear film stability indicators and immune function indicators were assessed and recorded.
Results: Prior to treatment, there was no significant difference in symptom score, inflammatory factors, tear film stability indicators and immune function indicators between study and control groups. Although the above indicators improved in both groups after treatment, the study group showed significantly greater improvement than control group (p < 0.05). Overall clinical response rate in the study group (95.83 %) was higher than in the control group (77.08 %), while the incidence of adverse reaction in the study group (6.25 %) was lower than that of control group (27.08 %, p < 0.05).
Conclusion: Pranoprofen eye drops, when combined with emedastine difumarate eye drops for treatment of children with allergic conjunctivitis, is more effective than the use of emedastine difumarate eye drops alone. However, further clinical trials are required to validate the findings of this study prior to adoption of the combination treatment in clinical practice.
Archives
News Updates
Fulltext in PDF